Autor(es):
Visca, D ; Centis, R ; Pontali, E ; Zampogna, E ; Russell, AM ; Migliori, GB ; Andrejak, C ; Aro, M ; Bayram, H ; Berkani, K ; Bruchfeld, J ; Chakaya, JM ; Chorostowska-Wynimko, J ; Crestani, B ; Dalcolmo, MP ; D’Ambrosio, L ; Dinh-Xuan, AT ; Duong-Quy, S ; Fernandes, C ; García-García, JM ; de Melo Kawassaki, A ; Carrozzi, L ; Martinez-Garcia, MA ; Carreiro Martins, P ; Mirsaeidi, M ; Mohammad, Y ; Naidoo, RN ; Neuparth, N ; Sese, L ; Silva, DR ; Solovic, I ; Sooronbaev, TM ; Spanevello, A ; Sverzellati, N ; Tanno, L ; Tiberi, S ; Vasankari, T ; Vasarmidi, E ; Vitacca, M ; Annesi-Maesano, I
Data: 2023
Identificador Persistente: http://hdl.handle.net/10400.17/4805
Origem: Repositório do Centro Hospitalar de Lisboa Central, EPE
Assunto(s): COVID-19 Testing; COVID-19*; Disease Progression; Educational Status; Exercise; Humans; Quality of Life*; HDE ALER
Descrição
BACKGROUND: The aim of these clinical standards is to provide guidance on 'best practice' care for the diagnosis, treatment and prevention of post-COVID-19 lung disease.METHODS: A panel of international experts representing scientific societies, associations and groups active in post-COVID-19 lung disease was identified; 45 completed a Delphi process. A 5-point Likert scale indicated level of agreement with the draft standards. The final version was approved by consensus (with 100% agreement).RESULTS: Four clinical standards were agreed for patients with a previous history of COVID-19: Standard 1, Patients with sequelae not explained by an alternative diagnosis should be evaluated for possible post-COVID-19 lung disease; Standard 2, Patients with lung function impairment, reduced exercise tolerance, reduced quality of life (QoL) or other relevant signs or ongoing symptoms ≥4 weeks after the onset of first symptoms should be evaluated for treatment and pulmonary rehabilitation (PR); Standard 3, The PR programme should be based on feasibility, effectiveness and cost-effectiveness criteria, organised according to local health services and tailored to an individual patient's needs; and Standard 4, Each patient undergoing and completing PR should be evaluated to determine its effectiveness and have access to a counselling/health education session.CONCLUSION: This is the first consensus-based set of clinical standards for the diagnosis, treatment and prevention of post-COVID-19 lung disease. Our aim is to improve patient care and QoL by guiding clinicians, programme managers and public health officers in planning and implementing a PR programme to manage post-COVID-19 lung disease.
